Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention
Key Points
Novo Nordisk competes with Eli Lilly in the GLP-1 space.
Novo Nordisk's recently launched GLP-1 pill could help reset the game.
- 10 stocks we like better than Novo Nordisk ›
Novo Nordisk (NYSE: NVO) hasn't been getting much love on Wall Street. The stock trades down 66% from its 2024 highs and just took a big hit after the company offered weak guidance for 2026. However, for contrarian dividend investors, Novo Nordisk could be an undervalued opportunity.
First, Novo Nordisk's bad news
Novo Nordisk was the first company to introduce a GLP-1 weight loss shot. Unfortunately, it couldn't keep up with demand, which allowed compounded versions of the company's Wegovy to be sold. And Eli Lilly (NYSE: LLY) launched its own GLP-1 drug, which proved more effective. So, at this point, Eli Lilly's Mounjaro and Zepbound are the leaders in the GLP-1 space.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
Adding to the company's woes is Novo Nordisk's weak guidance for 2026. Unlike Eli Lilly, which offered strong guidance, Novo Nordisk is expecting revenue and earnings to fall this year. Part of that comes from an agreement with the U.S. government around drug pricing. It is easy to see why Novo Nordisk is viewed as an also-ran in the GLP-1 space right now.
There's good news about Novo Nordisk
However, the news isn't all bad. Novo Nordisk was first to market with a pill version of its GLP-1 drug, beating Eli Lilly to the punch. That gives the company time to regain market share before Eli Lilly launches its own pill. Consumers tend to prefer pills to shots, for obvious reasons, and the uptake on Novo Nordisk's pill has been very strong. The hope is that the pill dramatically increases the number of customers taking GLP-1 drugs.
Also, the company is working on an updated version of its GLP-1 drug that is more competitive with Eli Lilly's offering. And Novo Nordisk appears to be taking a more aggressive approach with generic competitors, which could help it squeeze these players out now that the company's GLP-1 drug production is keeping up with demand.
Novo Nordisk looks cheap
Meanwhile, Novo Nordisk's price-to-earnings ratio is 13.5, compared to Eli Lilly's 45. And Novo Nordisk is offering an attractive 3.7% yield compared to Eli Lilly's 0.6%. Novo Nordisk's dividend is well supported, too, with a payout ratio of roughly 40%. While 2026 may be a turnaround year, there are compelling reasons to be positive about the future. If you are a dividend investor or have a value bias, you'll likely find Novo Nordisk an attractive option in the GLP-1 space.
Should you buy stock in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $420,595!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,152,356!*
Now, it’s worth noting Stock Advisor’s total average return is 899% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 19, 2026.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
